| P50 | author | Robert Graham G Russell | Q67903135 |
| P2093 | author name string | Frieder Bauss | |
| P2860 | cites work | Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group | Q28239579 |
| | Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. | Q31034846 |
| | Bisphosphonates: from the laboratory to the clinic and back again | Q33697467 |
| | Bisphosphonates: pharmacology, mechanisms of action and clinical uses | Q33753698 |
| | Characteristics of an ovariectomized osteopenic rat model | Q69606670 |
| | A one year follow-up study of the distribution of 14C-clodronate in mice and rats | Q70051344 |
| | Effects of long-term infusion of physiologic doses of 1-34 PTH on bone | Q70302121 |
| | The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat | Q71249878 |
| | Structural requirements for bisphosphonate actions in vitro | Q72582036 |
| | A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs | Q72671390 |
| | Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties | Q72691856 |
| | Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density | Q72763627 |
| | Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis) | Q73153006 |
| | Disuse bone loss in hindquarter suspended rats: partial weightbearing, exercise and ibandronate treatment as countermeasures | Q73275540 |
| | Treatment with ibandronate preserves bone in experimental tumour-induced bone loss | Q73498674 |
| | Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure | Q74160170 |
| | Bisphosphonates: mechanisms of action | Q74291014 |
| | Treatment of postmenopausal osteoporosis | Q74332861 |
| | Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines | Q33767974 |
| | Dosing regimens and main adverse events of bisphosphonates | Q34090289 |
| | Intravenous zoledronic acid in postmenopausal women with low bone mineral density | Q34116443 |
| | Pathogenesis of bone fragility in women and men. | Q34131375 |
| | Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies | Q34247899 |
| | How often is medication taken as prescribed? A novel assessment technique | Q34525872 |
| | The ovariectomized rat model of postmenopausal bone loss | Q34669140 |
| | Epidemiology and outcomes of osteoporotic fractures | Q34671295 |
| | Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies | Q35085359 |
| | On the rat model of human osteopenias and osteoporoses | Q35365332 |
| | Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women | Q35552068 |
| | Measuring compliance with inhaled medication in asthma | Q35627983 |
| | Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia | Q36115924 |
| | Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis | Q39395362 |
| | Overview of patient compliance with medication dosing: a literature review | Q40186921 |
| | Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection | Q40668608 |
| | Basic biomechanical measurements of bone: a tutorial | Q40797364 |
| | Remodeling and the repair of fatigue damage | Q40798061 |
| | Preclinical pharmacology of alendronate | Q40809403 |
| | The crippling consequences of fractures and their impact on quality of life | Q41597014 |
| | The socioeconomic burden of fractures: today and in the 21st century | Q41597021 |
| | Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study | Q41645618 |
| | Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation | Q43583991 |
| | Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis | Q43755577 |
| | Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats | Q44001436 |
| | The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis | Q44042152 |
| | Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats | Q44176120 |
| | Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. | Q44220762 |
| | Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study | Q44261951 |
| | Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys | Q44313218 |
| | Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases | Q44572717 |
| | Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats | Q44730464 |
| | New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate | Q44963511 |
| | The long-term effect of ovariectomy on the quality and quantity of cortical bone in the young cynomolgus monkey: a comparison of density fractionation and histomorphometric techniques | Q46296322 |
| | The relationship between three-dimensional connectivity and the elastic properties of trabecular bone | Q46771532 |
| | Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. | Q50876185 |
| | Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related protein | Q51607813 |
| | Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group | Q58971879 |
| | Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties | Q61760388 |
| | The bone "quality" problem | Q67573291 |
| | BM 21.0955, a potent new bisphosphonate to inhibit bone resorption | Q67906709 |
| | Pharmacokinetics of Clodronate after Single Intravenous, Intramuscular and Subcutaneous Injections in Rats | Q67907303 |
| | The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats | Q67923874 |
| | Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals | Q68332689 |
| | Bone changes occurring early after cessation of ovarian function in beagle dogs: a histomorphometric study employing sequential biopsies | Q68771472 |
| | Editorial: Single daily dose of antidepressants | Q68940693 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| P304 | page(s) | 423-433 | |
| P577 | publication date | 2004-03-26 | |
| P1433 | published in | Osteoporosis International | Q7107640 |
| P1476 | title | Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing | |
| P478 | volume | 15 | |